Navigation Links
ESTEVE Communicates its R&D Through a New Interactive Platform
Date:7/12/2012

BARCELONA, July 12, 2012 /PRNewswire/ --

This site is part of the  http://www.esteve.com  corporate web portal

  • ESTEVE's new website provides consise and updated information on its projects under development. Among these is the S1RA (Sigma-1 Receptor Antagonist), a new chemical entity, presently in Clinical Phase II, for treating several types of pain
  • In addition to defining the Company's main lines of research, this new website also discloses the Company's different and innovative models of collaboration

ESTEVE announces the launch of a new website (http://www.esteve.es/EsteveFront/IDI.do?lng=en) with the purpose of communicating the Company's R&D and the innovative models of collaboration currently implemented. Newly formatted and fully integrated in the http://www.esteve.com web portal, this site reinforces the commitment of ESTEVE to R&D with emphasis on a solid strategy to provide new therapeutic solutions for unmet medical needs in highly prevalent diseases of high social impact.

With its primary focus in analgesia, ESTEVE is developing innovative therapies for pain. Two projects are presently undergoing clinical development for the treatment of neuropathic pain and moderate to severe acute and chronic pain.

One of these projects involves S1RA, a highly selective Sigma-1 Receptor Antagonist that offers a new approach and a new mechanism of action in a field (neuropathic pain) strongly in need of novel, more effective and safer therapies.

The new website also describes the innovative partnering strategy in R&D as well as ESTEVE's network of excellence built through unique collaborative models. This network includes different types of alliances, from public-private partnerships -such as the HIVACAT program to develop an effective vaccine against HIV and the Sanfilippo project to develop a treatment for a rare childhood disease- to R&D consortiums such as Neogenius for pain research.

One of the key features of this site is its attractively designed interface for portfolio presentation, which includes the various ongoing R&D programs, i.e. in-house projects in analgesia, projects in collaboration with other centers or companies, and in-licensed projects.

With language and information customized for each audience, this new website provides specific information for scientists, healthcare providers, industry partners, patients and other stakeholders.

About ESTEVE

ESTEVE is a leading chemical-pharmaceutical group in Spain and has a strong international presence. Ever since its foundation in 1929, ESTEVE has been firmly committed to excellence and has been using its best efforts to promote health and improve people's quality of life.



'/>"/>
SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BIRD - Israel-US Binational Industrial R&D Foundation to Invest $7.15 Million in Eight New Projects
2. picoSpin-45 Miniature NMR Spectrometer Wins R&D 100 Award
3. ORNL wins 9 R&D 100s, bringing total to 173
4. New life sciences R&D model based on real-time learning and data-sharing needed to sustain innovation
5. Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. Mandy Moore Campaigns for Clean Water, GreenBeanBuddy Encourages Mothers to Help Through the Use of Green Cleaning Products
8. Innovation Leaders from Across Industries will Convene to Share Best Practices and Breakthrough Successes at Open Innovation Leadership Summit
9. Nanodiamonds cut through dirt to bring back bling to low-temperature laundry
10. Soundbites Breaks Through at 47th AES Conference
11. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... MCLEAN, Va. , March 27, 2017  Perthera,s ... Lombardi Cancer Center, Subha Madhavan , Ph.D., will ... 2017 Joint Summits Panels. On Monday, March 27, 2017, ... Precision Oncology Data More Usable for Research and Care" ... Tuesday, March 28, 2017, she will be a participant ...
(Date:3/27/2017)... MA (PRWEB) , ... March 27, 2017 , ... ... a method to engineer scalable and customizable vascular grafts in JoVE’s Video Journal, ... may lead to new and improved ways of treating coronary artery disease (CAD). ...
(Date:3/27/2017)... , March 27, 2017 Neurotrope, ... novel therapies for neurodegenerative diseases, including Alzheimer,s disease, ... its application to list the Company,s common stock ... by The NASDAQ Stock Market, a unit of ... listing, Neurotrope will ring the Opening Bell at the ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has ... Research - Global Strategic Business Report" report to their offering. ... This report ... in US$ Million. Annual estimates and forecasts are provided for the ... primary and secondary research. The report profiles 25 ...
Breaking Biology Technology:
(Date:2/26/2017)... 2017  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announces the appointment ... "Too often, too many offenders return to ... are trying to tackle this ongoing problem and ... family members. While significant steps are underway, Securus continues ...
(Date:2/22/2017)... 2017 With the biometrics market to ... four technologies that innovative and agile startups must ... in the changing competitive landscape: multifactor authentication (MFA), ... "Companies can no longer afford to ... Dimitrios Pavlakis , Industry Analyst at ABI ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
Breaking Biology News(10 mins):